A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Studiedetails
Type carcinoma: | NSCLC met mutatie |
---|---|
Stadium: | IV |
Mutatie: | EGFR |
Lijn: | 2de na osimertinib |
Site: | Erasmus MC |
Contactgegevens: | long.oncologie@erasmusmc.nl |
Website: | https://-/ |
Inclusiecriteria
Histologically or cytologically confirmed adenocarcinoma of the lung (patients with mixed histology are eligible if adenocarcinoma is the predominant histology) harbouring EGFR mutation(s) known to be associated with EGFR TKI sensitivity at diagnosis.
Received only 1 line of therapy, with single-agent osimertinib, for advanced NSCLC, with clinical benefit as judged by investigator discretion.
WHO 0-1
Exclusiecriteria
Patients whose disease has progressed within the first 3 months of osimertinib treatment (refractory to osimertinib treatment).
Patients should not have discontinued osimertinib >60 days prior to the first dose of study treatment.
Meer studies
Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:
TROPION-LUNG01
2de lijns | stadium IIIb-IV | AGA-positive
TEIPP
Stadium IV | 2de lijns
ORCHARD
EGFR | 2de lijn | stadium IV
MK-7684A
1ste lijn | Stadium IV
Mariposa
2de lijn | EGFR | stadium IIIIB - IV
KRYSTAL
Stadium IV | 2de lijn | KRAS G12C mutatie
ImmunoSABR
stadium IV - 1ste, 2de of 3de lijn
GENMAB
2de lijn - stadium IV
EVOKE
2de lijns | Stadium III/IV
Entrectinib
Stadium IIIB-IV | Eerstelijns | ROS1 mutation
Ensure
Eerstelijn | Fase I
CUP/EAP/DAP/DRUP
Lijst van verschillende programma's